TY - JOUR
T1 - Detection of circulating melanoma cells in the blood of melanoma patients
T2 - A preliminary study
AU - Roland, Christina L.
AU - Ross, Merrick I.
AU - Hall, Carolyn S.
AU - Laubacher, Barbara
AU - Upshaw, Joshua
AU - Anderson, Amber E.
AU - Lucci, Anthony
N1 - Publisher Copyright:
© 2015 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2015/7/11
Y1 - 2015/7/11
N2 - Significant prognostic heterogeneity exists within the substages of melanoma; therefore, novel prognostic biomarkers are needed to provide information on the risk of recurrence. Limited available data suggest prognostic significance for circulating melanoma cells (CMCs); there is a need for a sensitive, reproducible, and standardized identification technique. Using a semiautomated technology, we sought to determine whether CMCs could be identified reliably in stage I-IV melanoma patients and whether the presence of CMC correlated with known prognostic factors. CMCs were detected in the peripheral blood (7.5 ml) of patients with stage I-IV melanoma (n=89) using the CellSearch system. CD146 + cells were immunomagnetically enriched; nucleated HMW-MAA +/CD45-/CD34-cells were considered CMCs. One or more CMCs was detected in 45% of all patients, varying with stage of disease (stages I/II, III, and IV: 35, 44, and 86%, respectively; P=0.03, for stage I/II vs. stage IV); 55% had one CMC, 32% had two CMCs, and 13% had three or more CMCs identified. The presence of CMCs in the blood was associated with histologic subtype, particularly in patients with stage I/II disease (superficial spreading 18% vs. acral lentiginous 75%). Using a semiautomated technique, CMCs can be identified in a significant number of melanoma patients. These data support further study with longer follow-up and longitudinal/serial time points to better determine the identification rates and prognostic significance of CMCs in stage I-IV melanoma patients.
AB - Significant prognostic heterogeneity exists within the substages of melanoma; therefore, novel prognostic biomarkers are needed to provide information on the risk of recurrence. Limited available data suggest prognostic significance for circulating melanoma cells (CMCs); there is a need for a sensitive, reproducible, and standardized identification technique. Using a semiautomated technology, we sought to determine whether CMCs could be identified reliably in stage I-IV melanoma patients and whether the presence of CMC correlated with known prognostic factors. CMCs were detected in the peripheral blood (7.5 ml) of patients with stage I-IV melanoma (n=89) using the CellSearch system. CD146 + cells were immunomagnetically enriched; nucleated HMW-MAA +/CD45-/CD34-cells were considered CMCs. One or more CMCs was detected in 45% of all patients, varying with stage of disease (stages I/II, III, and IV: 35, 44, and 86%, respectively; P=0.03, for stage I/II vs. stage IV); 55% had one CMC, 32% had two CMCs, and 13% had three or more CMCs identified. The presence of CMCs in the blood was associated with histologic subtype, particularly in patients with stage I/II disease (superficial spreading 18% vs. acral lentiginous 75%). Using a semiautomated technique, CMCs can be identified in a significant number of melanoma patients. These data support further study with longer follow-up and longitudinal/serial time points to better determine the identification rates and prognostic significance of CMCs in stage I-IV melanoma patients.
KW - CellSearch
KW - circulating melanoma cells
KW - melanoma
UR - http://www.scopus.com/inward/record.url?scp=84936951782&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84936951782&partnerID=8YFLogxK
U2 - 10.1097/CMR.0000000000000168
DO - 10.1097/CMR.0000000000000168
M3 - Article
C2 - 26011119
AN - SCOPUS:84936951782
SN - 0960-8931
VL - 25
SP - 335
EP - 341
JO - Melanoma research
JF - Melanoma research
IS - 4
ER -